When Lyria 3 launched last month, Gemini could generate 30-second audio clips from prompts. With the new advanced model, the chatbot can now create tracks up to 3 minutes long and follow instructions ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Claude can now generate visuals when producing a response. (Anthropic) With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Generate Biomedicines shares dropped nearly 21% Friday after the company’s $400 million initial public offering, continuing an uneven recovery for biotech stock-market debuts. After a biotech IPO ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

I recently saw a tweet showing how Google has acquired companies over the years and built products around them. Here is the link to the tweet if you want. Now, Google made another announcement: Google ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...